JAKAVI® is available in four tablet strengths to enable dose optimisation for each patient1
The recommended starting dose for JAKAVI® is based on a patient’s platelet count at treatment initiation.1
- 15 mg twice daily for patients with a platelet count between 100,000/mm3 and 200,000/mm3
- 20 mg twice daily for patients with a platelet count of >200,000/mm3
There is limited information to recommend a starting dose for patients with platelet counts between 50,000/mm3 and <100,000/mm1.
The maximum recommended starting dose in patients with platelet counts between 50,000/mm3 and <100,000/mm3 is 5 mg twice daily and patients should be titrated cautiously.1
Optimise your patients’ response to therapy with dose titration that’s based on safety and efficacy1
Treatment may continue as long as benefit-risk balance remains positive. After interruption or discontinuation of JAKAVI® dosing, symptoms of myelofibrosis may return over a period of approximately 1 week. Unless abrupt discontinuation is required, gradual tapering of the dose may be considered, although the utility of tapering is unproven. Refer to the full Summary of Product Characteristics for further management guidance.1
JAKAVI® is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis. JAKAVI® is also indicated for adult patients with polycythaemia vera who are resistant to or intolerant of hydroxyurea.1
* For the full list of AEs, please refer to the SmPC.1
AE, adverse event; SmPC, summary of product characteristics.
- Novartis Pharmaceuticals UK Ltd. JAKAVI® summary of product characteristics.
- Polverelli N, et al. EHA 2016, 9–12 June; Copenhagen, Denmark. Abstract P672.
- Harrison C, et al. N Engl J Med. 2012;366:787–798.
- Verstovsek S, et al. Haematologica. 2013;98:1865–1871.